Titration

Vista Gold Drilling Confirms Adjacent Mineralized Zone at the Mt Todd Gold Project

Retrieved on: 
Monday, December 14, 2020
Natural sciences, Physical sciences, Chemistry, Assay, Biochemistry, Titration, Lode

The assay laboratories responsible for the assays were NAL Pty Ltd, Pine Creek, NT and Genalysis Laboratory Services Pty Ltd, Perth, WA.

Key Points: 
  • The assay laboratories responsible for the assays were NAL Pty Ltd, Pine Creek, NT and Genalysis Laboratory Services Pty Ltd, Perth, WA.
  • VB20-001 intersected the lode at the predicted location and encountered a thicker mineralized zone than anticipated.
  • The Companys flagship asset is the Mt Todd gold project in the Tier-1 mining jurisdiction of Northern Territory, Australia.
  • Mt Todd is the largest undeveloped gold project in Australia and if developed as presently designed, would potentially be Australias 6th largest gold producer on an annual basis.

Welldoc Submits 510(k) for Bolus and Premixed Insulin Titration Program as Part of BlueStar®

Retrieved on: 
Monday, December 14, 2020
FDA, Diabetes, Health, Clinical medicine, Medicine, Medical specialties, Diabetes, Peptide hormones, Recombinant proteins, Insulin, Basal, Bolus, Titration, Insulin pump

With the filing, BlueStar looks to add bolus and premixed insulin titration for type 2 diabetes to its comprehensive diabetes platform.

Key Points: 
  • With the filing, BlueStar looks to add bolus and premixed insulin titration for type 2 diabetes to its comprehensive diabetes platform.
  • In June, Welldoc announced FDA clearance for the BlueStar Insulin Adjustment Program for basal insulin titration.
  • This current submission would expand insulin dosing support to include most types of insulin.
  • By going digital, our new bolus and premixed insulin titration program goes beyond the pencil and paper processes we traditionally have relied upon to make the process of adjusting insulin easier and safer.

Compliance with New York State Winter COVID-19 Plan Drives Demand for Applied DNA’s Pooled Surveillance Testing Program

Retrieved on: 
Friday, December 11, 2020
Biotechnology, Health, Pharmaceutical, Other Education, Oncology, Other Science, University, Research, Infectious diseases, Education, Hospitals, Genetics, Science, Clinical trials, Natural sciences, Laboratory techniques, Physical sciences, Chemistry, Biotechnology, Assay, Biochemistry, Titration, Polymerase chain reaction, Coronavirus disease

safeCircle is a proprietary COVID-19 pooled surveillance testing program that utilizes the Companys PCR-based, Linea COVID-19 Assay Kit in conjunction with an automated, high-throughput testing workflow and equipment, software, and services to return de-identified aggregate pooled surveillance test results within 24 hours.

Key Points: 
  • safeCircle is a proprietary COVID-19 pooled surveillance testing program that utilizes the Companys PCR-based, Linea COVID-19 Assay Kit in conjunction with an automated, high-throughput testing workflow and equipment, software, and services to return de-identified aggregate pooled surveillance test results within 24 hours.
  • Our safeCircle program is a highly customizable solution that can be easily administered to deliver ongoing, consistent, and highly accurate surveillance testing proactively to protect schools and classrooms.
  • The program uses testing in pools of 5 individuals to avoid the potential for the dilution of an early positive sample.
  • ADCLs pooled surveillance testing program, known as safeCircle, utilizes frequent, high-sensitivity pooled testing to help prevent virus spread by quickly identifying infections within a community, school, or workplace.

Oxidative Stress Assay Market - Global Industry Trends, Share, Size, Growth, Opportunity and Forecasts, 2014-2019 & 2020-2025 - ResearchAndMarkets.com

Retrieved on: 
Friday, December 4, 2020
Health, Biotechnology, Branches of biology, Natural sciences, Chemistry, Assay, Biochemistry, Titration, Oxidative stress

The "Oxidative Stress Assay Market: Global Industry Trends, Share, Size, Growth, Opportunity and Forecast 2020-2025" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Oxidative Stress Assay Market: Global Industry Trends, Share, Size, Growth, Opportunity and Forecast 2020-2025" report has been added to ResearchAndMarkets.com's offering.
  • The global oxidative stress assay market grew at a CAGR of around 8% during 2014-2019.
  • Looking forward, the global oxidative stress assay market to continue its moderate growth during the next five years.
  • What is the structure of the global oxidative stress assay market and who are the key players?

Skyharbour Expands High Grade Maverick East Zone with Drill Results of 0.72% U3O8 over 17.5m including 1.00% U3O8 over 10.0m; Additional Assays Pending

Retrieved on: 
Thursday, December 3, 2020
Assay, Biochemistry, Titration

This interval returned 0.72% U3O8 over 17.5 metres and contained a basal high grade basement interval of 1.00% U3O8 over 10.0 metres.

Key Points: 
  • This interval returned 0.72% U3O8 over 17.5 metres and contained a basal high grade basement interval of 1.00% U3O8 over 10.0 metres.
  • The intercept confirms the potential of the central portion of the eastern extension of the Maverick East Zone.
  • The remaining assay results from the program are pending with planning for additional drilling at Moore Lake currently underway.
  • In 2017, Skyharbour announced drill results including 6.0% U3O8 over 5.9 metres including 20.8% U3O8 over 1.5 metres at a vertical depth of 265 metres.

Global COVID-19 Diagnostic Demand: Assay Volume Demand by Country with Forecasts to December 2021

Retrieved on: 
Friday, November 27, 2020
Laboratory techniques, Assay, Biochemistry, Titration

DUBLIN, Nov. 27, 2020 /PRNewswire/ -- The "COVID-19 Global Diagnostic Demand Outlook by Country, Assay Volume Quarterly Outlook to December 2021, Separately for Molecular and Serology.

Key Points: 
  • DUBLIN, Nov. 27, 2020 /PRNewswire/ -- The "COVID-19 Global Diagnostic Demand Outlook by Country, Assay Volume Quarterly Outlook to December 2021, Separately for Molecular and Serology.
  • This report looks at the assay volume demands by country looking out 5 quarters to the end of 2021.
  • The reoort looks at 3 scenarios for pandemic progression and explore diagnostics demand in each scenario.
  • These create varying timelines of demand.

FenixOro Intercepts Multiple High Grade Gold Veins in First Drill Hole at Abriaqui Including 32 g/t Gold

Retrieved on: 
Tuesday, November 24, 2020
Chemistry, Physical sciences, Natural sciences, Laboratory techniques, Assay, Biochemistry, Titration, Metallurgical assay, Drilling

TORONTO, Nov. 24, 2020 (GLOBE NEWSWIRE) -- FenixOro Gold Corp (CSE:FENX, OTCQB:FDVXF, Frankfurt:8FD) is pleased to announce that assay results from the first drill hole demonstrate high grade gold and silver intercepts at the Abriaqui project in Antioquia, Colombia.

Key Points: 
  • TORONTO, Nov. 24, 2020 (GLOBE NEWSWIRE) -- FenixOro Gold Corp (CSE:FENX, OTCQB:FDVXF, Frankfurt:8FD) is pleased to announce that assay results from the first drill hole demonstrate high grade gold and silver intercepts at the Abriaqui project in Antioquia, Colombia.
  • Assays returned from first hole, results pending on three additional holes completed
    Seven intercepts in hole P001001 including:
    FenixOro VP Exploration Stuart Moller commented: We are pleased that the drilling program at Abriaqui has had a promising start with the very first hole returning multiple intercepts of high grade gold mineralization.
  • Seven gold intercepts are highlighted in the table and there are four additional intercepts above the 2 g/t gold cutoff that are too thin to include.
  • The intercepts include individual sample grades as high as 32 g/t gold and the average silver to gold ratio is about 2:1.

Global Demand for COVID Diagnostics Explodes - Explore the Demand Outlook, Based on What Countries have Done in Q1, Q2 and Q3 - ResearchAndMarkets.com

Retrieved on: 
Monday, November 23, 2020
Infectious diseases, Biotechnology, Pharmaceutical, Health, Assay, Biochemistry, Titration

The "COVID-19 Global Diagnostic Demand Outlook by Country, Assay Volume Quarterly Outlook to December 2021, Separately for Molecular and Serology.

Key Points: 
  • The "COVID-19 Global Diagnostic Demand Outlook by Country, Assay Volume Quarterly Outlook to December 2021, Separately for Molecular and Serology.
  • Updated to Include Q1, Q2 & Q3 2020 Actuals Data."
  • This report looks at the assay volume demands by country looking out 5 quarters to the end of 2021.
  • The reoort looks at 3 scenarios for pandemic progression and explore diagnostics demand in each scenario.

Aptima HIV-1 Quant Dx Assay Receives Additional FDA Approval for Use as an Aid in the Diagnosis of HIV Infection

Retrieved on: 
Friday, November 20, 2020
Infectious diseases, FDA, AIDS, Health, Medical specialties, HIV/AIDS, Clinical medicine, Health, Medical tests, Virology, Laboratory techniques, Assay, Titration, Viral load, HIV, Viral load monitoring for HIV

The Aptima HIV-1 Quant Dx assay is now the first dual-claim assay for both diagnosis and viral load monitoring in the United States.

Key Points: 
  • The Aptima HIV-1 Quant Dx assay is now the first dual-claim assay for both diagnosis and viral load monitoring in the United States.
  • View the full release here: https://www.businesswire.com/news/home/20201120005242/en/
    Aptima HIV-1 Quant Dx assay (Photo: Business Wire)
    The Aptima HIV-1 Quant Dx assay, which was approved in late 2016 for viral load monitoring, is a molecular diagnostic test that runs on the fully automated, sample-to-result Panther system.
  • The Aptima HIV-1 Quant Dx assay is also CE IVD-marked for both diagnostic and viral load monitoring claims.
  • A simultaneous viral load measurement with diagnosis will allow healthcare providers to guide treatment choices for patients to begin therapy immediately.

New Test for Triaging Preeclampsia Passes Key Development Milestone: Progenity Releases Prospective Clinical Verification Data for its Preecludia™ Test

Retrieved on: 
Friday, November 20, 2020
Natural sciences, Assay, Biochemistry, Titration, Nature, Women's health

Preeclampsia is the second most common cause of maternal mortality, and more than 700,000 women present each year with signs and symptoms of possible preeclampsia.

Key Points: 
  • Preeclampsia is the second most common cause of maternal mortality, and more than 700,000 women present each year with signs and symptoms of possible preeclampsia.
  • The Preecludia test is being developed to serve as a potential triage and rule-out test to help providers differentiate between patients with symptoms who are at risk for preeclampsia.
  • This proprietary test is a multi-analyte protein biomarker assay which is designed to be run from a simple blood draw.
  • Progenity will provide a thorough review of preeclampsia, its cost to the healthcare system, and the Preecludia test development program during a Preeclampsia R&D Day presentation on November 20, 2020, from 8-10 AM Pacific.